Discover
VCYT
Veracyte, Inc.
59.85
2 x 43.62
2 x 75.72
bid
ask
+
1.12
1.91%
2 @ 04:00 PM
59.83 -0.02 (0.03%)
| Ytd | 42.16% | |
| 1y | 119.07% |
58.75
day range
60.69
22.61
52 week range
60.91
| Open | 58.99 | Prev Close | 58.73 | Low | 58.75 | High | 60.69 | Mkt Cap | 4.78B |
| Vol | 1.19M | Avg Vol | 1.15M | EPS | 1.08 | P/E | 55.42 | Forward P/E | 30.89 |
| Beta | 1.98 | Short Ratio | 6.89 | Inst. Own | 113.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 44.69 | 200-d Avg | 39.48 | 1yr Est | 49.10 |
VCYT News
benzinga.com
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price t
fool.com
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K
benzinga.com
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
benzinga.com
Needham Maintains Buy on Veracyte, Raises Price Target to $57
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ
benzinga.com
Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S.
On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, In